Novo Nordisk Knew About Gastroparesis Risk — Evidence
If you are exploring fda-news, this comprehensive resource breaks down the latest evidence, practical tips, and expert insights to help you make informed decisions about your health journey.
Regulatory Timeline
The timeline of safety communications about GLP-1 medications reveals a series of events that lawyers assert demonstrates corporate knowledge of serious risks prior to their being added to drug labels.
Important dates include:
- 2017: Original semaglutide approval for glycemic control
- 2021: Semaglutide 2.4mg approval
- 2022: Tirzepatide approval
- 2023-2024: Growing body of gastroparesis reports
- 2024: Academic research confirms elevated risks
- 2024-2025: Label updates adding serious adverse event disclosures
- 2025-2026: Consolidated litigation begins
Why This Matters for Your Case
The regulatory record serves as key documentation because it may show:
- What the manufacturer knew and how long they had the information
- Whether warnings were adequate — were patients and doctors accurately communicate the dangers
- Delayed disclosure — periods where internal knowledge and public warning
- Regulatory pressure — whether the company resisted label changes
The FDA record bolsters the central claim in the Ozempic litigation: that the manufacturers prioritized profits over safety.
Think you may have a case? Get a free, confidential case evaluation from an experienced GLP-1 litigation attorney.
This information is for educational purposes only and does not constitute legal advice. Past results do not guarantee future outcomes.
Frequently Asked Questions
Are there things to watch out for related to fda-news?
Like most health considerations, there are nuances that deserve attention. Talk about potential issues with your healthcare team to get personalized guidance.
Where can I find additional resources on fda-news?
Credible references are your healthcare provider including the FDA and the Endocrine Society. Always confirm claims through professional consultation.
What should I discuss with my physician about fda-news?
Open with asking about how this applies to your specific situation. Your doctor can tailor advice considering your health history and existing prescriptions.